Bempedoic acid (ETC-1002), an ATP citrate lyase (ACLY) inhibitor that lowers LDL cholesterol, was recently approved by the US FDA for the treatment of heterozygous familial hypercholesterolemia (HeFH) and established atherosclerotic cardiovascular disease (ASCVD). Here, ACLY is linked to familial hypercholesterolemia.